行情

VTVT

VTVT

VTV THERAPEUTICS
NASDAQ

实时行情|Nasdaq Last Sale

1.540
+0.030
+1.99%
交易中 15:06 12/12 EST
开盘
1.530
昨收
1.510
最高
1.550
最低
1.500
成交量
9.53万
成交额
--
52周最高
3.500
52周最低
1.000
市值
9,225.68万
市盈率(TTM)
-2.6033
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VTVT 新闻

  • V&M Premium Portfolio: 2019 End Of Year Report Card Through Week 49
  • Seeking Alpha - Article.2天前
  • 5 Safe And Cheap Dividend Stocks To Invest (December 2019)
  • Seeking Alpha - Article.5天前
  • Top Holdings Of Dividend ETFs (Part 2: The Top 7 By Sector In November 2019)
  • Seeking Alpha - Article.5天前
  • Comcast: Undervalued After Recent Pullback
  • Seeking Alpha - Article.6天前

更多

所属板块

生物技术和医学研究
+1.00%
制药与医学研究
+0.67%

热门股票

名称
价格
涨跌幅

VTVT 简况

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of orally administered small molecule drug candidates. Its drug candidate for the treatment of Alzheimer's disease (AD) is azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts (RAGE), for which it has commenced patient enrollment in a Phase III clinical trial. Its type II diabetes drug candidates include TTP399, an orally administered, liver-selective glucokinase activator (GKA), for which it has completed enrollment in its Phase IIb clinical trial, and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor (GLP-1r), for which it began enrollment in a Phase II clinical trial. It has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders.
展开

Webull提供vTv Therapeutics Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。